OTS

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Lymphoma, Marker, OTS, D, ODD, SBIR, Drug discovery, European Medicines Agency, HMA, Research, Bangladesh Technical Education Board, Committee, EMA, U.S. FDA, APOLLO, CAR, AML, CDMO, Patient, Small Business Innovation Research, Neoplasm, R, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, NIH, Food, Bone marrow, Pharmaceutical industry, Management, Vaccine, Fine chemical, Nursing, Medical imaging, Cryptocurrency, MPH

Second Quarter 2023 Financial Highlights:

Key Points: 
  • Second Quarter 2023 Financial Highlights:
    Cash Position: At June 30, 2023, Marker had cash and cash equivalents of $18.1 million.
  • R&D Expenses: Research and development expenses from continuing operations were $2.4 million for the quarter ended June 30, 2023, compared to $2.9 million for the quarter ended June 30, 2022.
  • G&A Expenses: General and administrative expenses from continuing operations were $2.5 million for the quarter ended June 30, 2023, compared to $3.1 million for the quarter ended June 30, 2022.
  • Net Income (Loss): Marker reported net income of $2.5 million for the quarter ended June 30, 2023, compared to a net loss of ($9.2) million for the quarter ended June 30, 2022.

Brooks Rehabilitation Continues Expansion in Orlando Market, Announces New Physical Therapy Outpatient Clinic in Horizon West

Retrieved on: 
Thursday, August 17, 2023
CSCS, Life, OTS, SLP, Culture, Poinciana, Winter Garden, PT, Buenaventura Lakes, Florida, Occupational therapy, Suite, Rehabilitation, Waterford Lakes, Florida, Patient, Hand, Growth, Anatomical pathology, PTS, Hybrid, Sports medicine, Hospital, Central Florida, Cyberdyne, MetroWest

ORLANDO, Fla., Aug. 17, 2023 /PRNewswire/ -- Brooks Rehabilitation continues to grow in the Orlando market to address the demand for – and to provide necessary access to – physical therapy (PT), occupational therapy (OT) and speech-language pathology (SLP). The nonprofit will open its 12th Central Florida outpatient clinic August 23 in Horizon West at 15820 Shaddock Drive, Suite 110, Winter Garden, FL 34787.

Key Points: 
  • The nonprofit will open its 12th Central Florida outpatient clinic August 23 in Horizon West at 15820 Shaddock Drive, Suite 110, Winter Garden, FL 34787.
  • Brooks is currently accepting patients at its new Horizon West clinic, located off Porter Road directly across from Orlando Health Horizon West Hospital.
  • Physical therapy services at Horizon West include sports medicine, orthopedic physical therapy, post-operative physical therapy, geriatric physical therapy and worker's compensation.
  • The Horizon West clinic joins the growing number of Brooks outpatient clinics throughout the state, bringing the total number to 51.

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Retrieved on: 
Monday, August 7, 2023
Immortalised cell line, Graft-versus-host disease, Marker, OTS, GVHD, Blood, HLA, Leukemia, Allele, Baylor University, HSCT, Assistant, THP-1 cell line, Development, AML, Patient, Risk, Baylor College of Medicine, VST, FDA, Therapy, Biomedical Advanced Research and Development Authority, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Bone marrow, Vaccine, Medical imaging, Pharmaceutical industry, Medical device, Research

Leukemic cell growth was significantly reduced when treated with MT-401 OTS.

Key Points: 
  • Leukemic cell growth was significantly reduced when treated with MT-401 OTS.
  • Marker has established a cellular inventory of 8 lines manufactured from healthy donors, with ongoing efforts to further expand the inventory.
  • Marker anticipates that the first patient will be treated with MT-401 OTS during the first half of 2024.
  • If MT-401 OTS is successful in clinical trials, we will consider expanding the OTS multiTAA-specific T cell program to other indications with unmet medical needs,” concluded Dr. Vera.

OTS, Caltrans, CHP and AAA Announce New “Better Slow Than Sorry” Media Campaign to Raise Awareness About the Dangers of Speeding

Retrieved on: 
Monday, July 17, 2023
Public Transport, Other Transport, Marketing, Transport, Advertising, Law Enforcement, Emergency Services, Communications, Public Policy, Government, State, Local, California Highway Patrol, OTS, Road traffic safety, Education, Friends, CHP, Fourth, Automobile Club of Southern California, Death, Walking, California Office of Environmental Health Hazard Assessment, BMW, AAA, Risk, Radio, Crash, News, PSA, Social media, Injury, Road, Video game, California Department of Transportation

Audio messages encourage drivers to drive like their closest friends or family live in the neighborhood, and that speeding is dangerous for everyone, especially people biking or walking.

Key Points: 
  • Audio messages encourage drivers to drive like their closest friends or family live in the neighborhood, and that speeding is dangerous for everyone, especially people biking or walking.
  • “Speeding is a dangerous choice that can have deadly consequences for everyone on our roads,” said OTS Director Barbara Rooney.
  • In May, the CHP launched a “Thrills That Kill” education campaign that calls attention to the dangers of street racing, which further complements anti-speeding messages.
  • To view the new PSA and learn about other helpful ways to stay safe on the go, visit www.gosafelyca.org .

Drug Delivery -- Evaluating Off-The-Shelf and Novel Drug Delivery Solutions, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, June 26, 2023
OTS, Partnership, Specialization, Engineering, Administration, ISO, CXO, Åkerö, Knowledge, R, Demand generation, FDA, Vaccine, Medical device

TORONTO, June 26, 2023 /PRNewswire-PRWeb/ -- In the rapidly evolving field of drug delivery systems, understanding the tradeoffs and best practices when considering off-the-shelf (OTS) platforms versus novel development is critical. In an upcoming free webinar, industry leaders will delve into these critical aspects.

Key Points: 
  • In this free webinar, learn about the important tradeoffs when considering an off-the-shelf (OTS) drug delivery platform vs. novel development.
  • Attendees will understand best practices for novel drug delivery design and development.
  • TORONTO, June 26, 2023 /PRNewswire-PRWeb/ -- In the rapidly evolving field of drug delivery systems, understanding the tradeoffs and best practices when considering off-the-shelf (OTS) platforms versus novel development is critical.
  • The free webinar titled "Drug Delivery — Evaluating Off-The-Shelf and Novel Drug Delivery Solutions", will take place on Tuesday, July 11, 2023, at 1pm EDT (10am PDT).

California Office of Traffic Safety and Caltrans Kick Off NASCAR Race Weekend with “Go Safely” Meet and Greet with Driver Ross Chastain

Retrieved on: 
Friday, June 9, 2023
General Automotive, Public Safety, Law Enforcement, Emergency Services, Other Transport, Automotive, Public Policy, Government, Advocacy Group Opinion, Transport, Sports, Public Transport, Motor Sports, Communications, Social Activism, State, Local, Melon, OTS, Partnership, Chastain, Road traffic safety, Habit, California Department, California Highway Patrol, National Highway Traffic Safety Administration, Fatality, Sonoma Raceway, Multimedia, Toyota, NASCAR Cup Series, Death, California Office of Environmental Health Hazard Assessment, NASCAR, Crash, Social media, Safety, Injury, Road, California Department of Transportation

The California Office of Traffic Safety (OTS) and California Department of Transportation (Caltrans) teamed up with NASCAR Cup Series driver Ross Chastain today for a public meet and greet to encourage all Californians to Go Safely.

Key Points: 
  • The California Office of Traffic Safety (OTS) and California Department of Transportation (Caltrans) teamed up with NASCAR Cup Series driver Ross Chastain today for a public meet and greet to encourage all Californians to Go Safely.
  • The event included an up-close look at Chastain’s race car, traffic safety demonstrations, and autograph and photo opportunities.
  • “I am thankful to partner with the California Office of Traffic Safety and Caltrans to bring the Go Safely campaign to race fans,” said Ross Chastain.
  • “Our goal is to create a safety culture that does not accept that traffic deaths and serious injuries are inevitable.

Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Wednesday, May 31, 2023
Cervical cancer, Interim, US Foods, OTS, Precigen, Progression-free survival, SC, DCR, CMC, RECIST, BOR, Infection, Immunotherapy, Doctor of Philosophy, PFS, ASCO, Investigational New Drug, American Society of Clinical Oncology, Patient, Annual general meeting, HPV, Trial of the century, Infrared spectroscopy correlation table, Secondary, FDA, Pembrolizumab, Abstract, IND, Society, ORR, Food, Safety, Pharmaceutical industry

The Phase 2 randomized, open-label, two-arm, multicenter study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer who are pembrolizumab resistant.

Key Points: 
  • The Phase 2 randomized, open-label, two-arm, multicenter study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer who are pembrolizumab resistant.
  • The study will enroll approximately 46 patients who previously have been treated with pembrolizumab for recurrent or metastatic disease.
  • In the Phase 1 study, PRGN-2009 was evaluated as a monotherapy (N=6) and in combination with a checkpoint inhibitor (N=11) in patients with recurrent or metastatic human papillomavirus (HPV)-associated cancers.
  • Patients in the Phase 2 study will be randomized 1:1 to the combination of PRGN-2009 and pembrolizumab (cohort 1) or pembrolizumab monotherapy (cohort 2).

Join the #GoSafelyMovement: The OTS Launches Statewide Campaign to Address Roadway Crisis and Create Safety Culture

Retrieved on: 
Monday, May 15, 2023
Public Transport, Other Transport, Automotive, General Automotive, Transport, Law Enforcement, Emergency Services, Communications, Public Policy, Government, Social Activism, Public Safety, California Highway Patrol, OTS, Road traffic safety, Culture, National Highway Traffic Safety Administration, California State Transportation Agency, CHP, Hardship, Death, Movement, The Go, Crash, California Office of Environmental Health Hazard Assessment, Safety, Injury, Road, California Department of Transportation

To address this crisis on our roads, the California Office of Traffic Safety (OTS) today is launching the “ Go Safely Movement ” campaign with the help of its traffic safety partners the California State Transportation Agency (CalSTA), California Department of Transportation (Caltrans) and California Highway Patrol (CHP).

Key Points: 
  • To address this crisis on our roads, the California Office of Traffic Safety (OTS) today is launching the “ Go Safely Movement ” campaign with the help of its traffic safety partners the California State Transportation Agency (CalSTA), California Department of Transportation (Caltrans) and California Highway Patrol (CHP).
  • The campaign aims to establish a strong safety culture in California by raising awareness of the roadway crisis and encouraging people to take a Community Call to Action Survey .
  • Results of the survey will help inform the OTS’ highway safety planning efforts and identify “traffic safety champions” to promote more community-level involvement in traffic safety initiatives.
  • “We can no longer accept death and serious injuries as just a consequence of using our roads,” said OTS Director Barbara Rooney.

Conventus Flower Orthopedics Appoints Anjan R. Shah, MD as Chief Medical Officer

Retrieved on: 
Tuesday, May 2, 2023
OTS, University, Journal of Orthopaedic Trauma, Boston University Chobanian & Avedisian School of Medicine, Education, Trauma, Research, Drexel University, Boston University School of Public Health, Publication, MD, Patient, Orthopedic surgery, FOI, Health, Hospital, Nursing

HORSHAM, Pa., May 2, 2023 /PRNewswire/ -- Conventus Flower Orthopedics, an innovation-driven medical technology company, today announced the appointment of Anjan R. Shah, MD as its Chief Medical Officer.

Key Points: 
  • HORSHAM, Pa., May 2, 2023 /PRNewswire/ -- Conventus Flower Orthopedics, an innovation-driven medical technology company, today announced the appointment of Anjan R. Shah, MD as its Chief Medical Officer.
  • "Dr. Shah is a highly regarded surgeon with extensive clinical and education experience in the field of orthopedic trauma.
  • Our team looks forward to partnering with him to help serve patients and the industry," said Brad Niemann, CEO, Conventus Flower Orthopedics.
  • "I am excited about this opportunity to work with the leadership team at Conventus Flower Orthopedics.

Liberty Bankers Insurance Group Honored as Gold Stevie® Award Winner in 2023 American Business Awards®

Retrieved on: 
Monday, May 1, 2023
OTS, Life, Stevie Awards, Financial services, Marriott Marquis, Sale, Organization, Medicare, American business history, Gold, Artificial intelligence, Health, Medigap, New product development, U.S.A

DALLAS, May 1, 2023 /PRNewswire/ -- Liberty Bankers Insurance Group (LBIG), a nationally recognized provider of life, health, and financial products, was named the winner of a Gold Stevie® Award in the New Product and Services, Financial Services category in The 21st Annual American Business Awards® today.

Key Points: 
  • DALLAS, May 1, 2023 /PRNewswire/ -- Liberty Bankers Insurance Group (LBIG), a nationally recognized provider of life, health, and financial products, was named the winner of a Gold Stevie® Award in the New Product and Services, Financial Services category in The 21st Annual American Business Awards® today.
  • LBIG received this honor for its enhancements to the On-the-Spot (OTS) underwriting process for Medicare Supplement applications.
  • "We are pleased to be recognized for our On-the-Spot innovation," said Eric Johansson, executive vice president and chief operations officer of Liberty Bankers Insurance Group.
  • The American Business Awards are the U.S.A.'s premier business awards program.